Addex Therapeutics (ADXN) Receivables - Net (2018 - 2026)
Addex Therapeutics (ADXN) posted Receivables - Net of $40853.9 for Q1 2026, up 62.56% sequentially from $25132.2 in Q4 2025, and up 3.87% YoY from $39330.3 in Q1 2025.
Addex Therapeutics (ADXN) Receivables - Net (2018 - 2026) Analysis & Trends
Addex Therapeutics has reported Receivables - Net for 9 years, with the latest figure at $40853.9 in Q1 2026.
- Quarterly Receivables - Net rose 3.87% year-over-year to $40853.9 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $40853.9 (up 3.87% YoY) and the FY2025 annual result came in at $24227.5, down 78.69% from the prior year.
- Receivables - Net advanced to $40853.9 in Q1 2026 per ADXN's latest filing, from $25132.2 in the prior quarter.
- Over five years, Receivables - Net peaked at $647893.3 in Q2 2024 and troughed at $25132.2 in Q4 2025.
- A 5-year average of $236127.7 and a median of $208617.2 in 2023 frame the typical range for Receivables - Net.
- The sharpest annual moves came in 2022 and 2025: Receivables - Net jumped 390.85% in 2022, then slumped 92.83% in 2025.
- Over 5 years, Receivables - Net stood at $432725.4 in 2022, then plunged by 71.25% to $124416.0 in 2023, then declined by 8.25% to $114152.2 in 2024, then slumped by 77.98% to $25132.2 in 2025, then surged by 62.56% to $40853.9 in 2026.
- According to Business Quant data, Receivables - Net over the past three periods registered $40853.9, $25132.2, and $64064.4 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Addex Therapeutics | 534.71 Mn | 534.71 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 40,853.93 |
| Mar 31, 2026 | 40,853.93 |
| Dec 31, 2025 | 25,132.25 |
| Dec 31, 2025 | 25,132.25 |
| Sep 30, 2025 | 64,064.36 |
| Sep 30, 2025 | 64,064.36 |
| Jun 30, 2025 | 46,430.09 |
| Jun 30, 2025 | 46,430.09 |
| Mar 31, 2025 | 39,330.29 |
| Mar 31, 2025 | 39,330.29 |
| Dec 31, 2024 | 114,152.18 |
| Dec 31, 2024 | 114,152.18 |
| Sep 30, 2024 | 554,026.40 |
| Sep 30, 2024 | 554,026.40 |
| Jun 30, 2024 | 647,893.25 |
| Jun 30, 2024 | 647,893.25 |
| Mar 31, 2024 | 133,180.99 |
| Mar 31, 2024 | 133,180.99 |
| Dec 31, 2023 | 124,415.97 |
| Dec 31, 2023 | 124,415.97 |